Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.570
+0.0305.56%
Volume:212.22K
Turnover:118.14K
Market Cap:139.43M
PE:-22.69
High:0.580
Open:0.550
Low:0.520
Close:0.540
52wk High:1.435
52wk Low:0.091
Shares:244.62M
Float Shares:102.11M
Volume Ratio:0.66
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.025
EPS(LYR):-0.024
ROE:-71.00%
ROA:-41.98%
PB:14.16
PE(LYR):-23.53

Loading ...

Company Profile

Company Name:
NYRADA INC-CDI
Exchange:
ASX
Establishment Date:
2017
Employees:
- -
Office Location:
Sydney Place,Level 22/23, Salesforce Tower,180 George Street,Sydney,New South Wales,Australia
Zip Code:
2000
Fax:
61 2 9416 0810
Introduction:
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company was founded in 2017 and is based in Gordon, Australia.